UK – NICE rejects Novartis’ Mayzent for secondary progressive MS

NICE has turned down NHS funding in preliminary guidelines for use of Novatis' Mayzent (siponimod) as a treatment for secondary progressive multiple sclerosis (SPMS) with evidence of active disease.

According to the Institute, clinical trial results show that the drug reduces the number of relapses and slows disability progression compared with placebo.

However, it is uncertain how effective Mayzent is compared with interferon beta-1b – the only disease-modifying treatment available for people with active SPMS – because there is no evidence directly comparing them.

‘Because of the limited clinical evidence, the cost-effectiveness estimates are uncertain, and none of the analyses reflect the committee’s preferred assumptions. Therefore, siponimod is not recommended’, according to the draft guideline…